Merck's omarigliptin non-inferior to Januvia

Merck & Co. Inc. (NYSE:MRK) said omarigliptin ( MK-3102) met the primary endpoint of non-inferiority to Januvia sitagliptin in a Phase III trial to treat Type II diabetes. The once weekly dipeptidyl peptidase-4 ( DPP-4) inhibitor and Januvia, a DPP-4 inhibitor taken daily, produced similar reductions in HbA1c among patients taking metformin.

Omarigliptin reduced baseline HbA1c by 0.47% after 24 weeks, compared to 0.43% for Januvia in the 642-patient study. ...